
NPPA orders checks on 137 cancer medicines
State drug controllers must verify prices across pharmacies and hospitals and report violations by November 16.
Overview
Cancer patients in India may pay less for 137 . The move follows a expert committee’s findings on high trade margins. In an October 17 order, the capped those margins at 30%. It did not put every medicine under legal price control. New for 1,364 formulations and 543 brands began on November 9. The prices use from March 2026, with GST added separately.
The savings will depend on enforcement. must check drug makers, dealers, hospitals and medical institutions. They must review labels, invoices and sale prices, then report action by November 16. Patients can compare prices on the published brand list, keep bills and report overcharging. Uneven reporting, outdated prices or non-compliance could limit the policy’s effect.
Timeline
The government told patients to check revised MRPs before paying for affected medicines
Patients can compare the product's revised with the 's published brand list and check that pharmacies and institutions charge no more than the applicable , apart from GST where permitted. They should retain bills and report suspected overcharging to the relevant or . The policy's practical effect depends on revised prices reaching labels, invoices, pharmacies and hospital bills.
NPPA required State drug controllers to submit action-taken reports by November 16
NPPA set November 16, 2026, as the deadline for State drug controllers to submit . The reports are intended to show whether states inspected sellers and institutions, checked implementation and acted on violations. The deadline measures enforcement activity, not merely whether the central order was issued.
NPPA directed State drug controllers to monitor compliance across the supply chain
NPPA directed to monitor manufacturers, dealers, hospitals and medical institutions implementing the 30% trade-margin cap. The enforcement chain includes checking revised labels, invoices and selling prices, identifying overcharging and requiring corrective action. Non-compliance can trigger .
NPPA brought revised MRPs for 1,364 formulations and 543 brands into effect
The revised MRPs became effective nationwide on November 9, 2026, covering 1,364 formulations and 543 brands. The new MRP is calculated from the reported for March 2026, with the trade margin capped at 30% and GST added separately. The reduction therefore varies by medicine, strength, brand and distribution channel.
Pharmaceutical companies reported revised MRPs for 1,364 formulations across 121 drugs
By November 8, 85 pharmaceutical companies had reported revised MRPs for 1,364 covering 121 of the affected drugs. The larger formulation count reflects different strengths, dosage forms and brands linked to the same drug or molecule. Brand-level MRPs can therefore differ even when products contain the same .
NPPA capped trade margins at 30% for 137 non-scheduled anti-cancer medicines
The issued , capping the trade margin on 137 non-scheduled anti-cancer medicines at 30% of the MRP. The order covered manufacturers, distributors and retailers, including medicines that were not already under the . It changed the permitted margin structure without fixing one identical price for every brand.
A DGHS expert committee recommended tighter margins on non-scheduled anti-cancer medicines
The expert committee recommended action over high trade margins on . The recommendation led to rather than placing every medicine under statutory price control. The approach limits the margin within the maximum retail price, while the MRP is recalculated from reported distributor prices.